CTOs on the Move

Cogent Biosciences

www.cogentbio.com

 
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent`s lead therapeutic candidate, PLX9486 (expected to be named CGT9486 in the future), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cogentbio.com
  • 200 CambridgePark Drive
    Cambridge, MA USA 02140
  • Phone: 617.945.5576

Executives

Name Title Contact Details

Similar Companies

Seed Health

Seed Health is a microbial sciences company pioneering applications of microbes for human and planetary health. In collaboration with leading academic researchers, we advance breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics, consumer health innovations and environmental solutions.

CLONTECH Laboratories

Clontech Laboratories, Inc. develops, produces, and markets innovative biological products to the life science market worldwide. Clontech is a wholly owned subsidiary of Takara Bio, Inc. Learn more about latest Clontech technologies:

Trident Health System

Trident Health is the leading provider of laboratory and mobile imaging services to the long term care community in the US. Operating in 43 states, we currently provide these services to more than 5,000 of the 16,000+ long term care facilities in the US.

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.

Volastra Therapeutics

Volastra aims to extend the lives of patients with cancer by leveraging unique insights into chromosomal instability. Moving away from primary tumor models to target the site of metastasis in the toughest-to-treat solid tumors, we are altering the treatment paradigm for metastatic cancers.